New hope for seizing newborns: First-Line drug trial shows promise
NCT ID NCT02229123
Summary
This study tested whether levetiracetam, an anti-seizure medication, is safe and effective as the first treatment for seizures in newborn babies who experienced oxygen deprivation around birth. Researchers gave the drug to 18 full-term newborns within their first 3 days of life to find the best dose that controls seizures without causing serious side effects. The goal was to develop better treatment options for these vulnerable infants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEONATAL SEIZURES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Néonatologie
Rennes, 35000, France
-
Service de Néonatologie
Tours, 37 000, France
-
Service de Pédiatrie néonatale et réanimation
Rouen, 76031, France
-
Service de réanimation et service néonatale
Orléans, 45100, France
-
Service de réanimation néonatale
Angers, 49000, France
-
Service de réanimation néonatale
Lille, 59037, France
-
Service de réanimation néonatale
Reims, 51092, France
-
Service de réanimation néonatale et pédiatrique
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.